Analysis of point mutations and copy number variation in Grade II and III meningioma

Samantha N. McNulty, Katherine Schwetye, Michael Goldstein, Jamal H. Carter, Robert E. Schmidt, George Ansstas, Christina I. Tsien, Albert H. Kim, Sonika Dahiya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Meningiomas are among the most common tumors of the adult central nervous system (CNS). They are classified by the World Health Organization into three pathologic grades with increasing severity: grade I are benign with favorable treatment outcomes and low recurrence rates while grade III display malignant behavior and poor progression-free survival. Previous studies have shown that inactivation of NF-2 is the most common genetic event in high-grade meningioma; however, there is dearth of molecular data to distinguish grade II (AM-II) from the even more aggressive grade III (AM-III). As part of a routine diagnostic workup, 19 AM-II and 5 AM-III were submitted for targeted sequencing on a panel of twenty-four genes relevant to CNS tumors. The data generated during the course of clinical care was collected and re-analyzed with the aim of identifying molecular features to distinguish AM-II and AM-III. Our cases contained several well-characterized, potentially actionable mutations, but we did not find any novel, recurrent sequence variants. Copy number variations were common in both AM-II and AM-III; chr22q loss was the most prevalent followed in decreasing frequency by losses of chr1p, chr14q, and chr10. In particular, chr10 loss was noted in 4 of 5 AM-III cases but none of the AM-II cases. This suggests that chr10 loss may serve as a diagnostic and perhaps a prognostic marker to differentiate AM-II from AM-III. If confirmed in larger studies, our finding could further aid the classification of meningioma.

Original languageEnglish (US)
Pages (from-to)328-333
Number of pages6
JournalExperimental and Molecular Pathology
Volume105
Issue number3
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Meningioma
Point Mutation
Central Nervous System Neoplasms
Neurology
Tumors
Disease-Free Survival
Recurrence
Mutation
Genes
Health

Keywords

  • Clinical sequencing.
  • Copy number variation.
  • Meningioma
  • Next-generation sequencing.

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Analysis of point mutations and copy number variation in Grade II and III meningioma. / McNulty, Samantha N.; Schwetye, Katherine; Goldstein, Michael; Carter, Jamal H.; Schmidt, Robert E.; Ansstas, George; Tsien, Christina I.; Kim, Albert H.; Dahiya, Sonika.

In: Experimental and Molecular Pathology, Vol. 105, No. 3, 01.12.2018, p. 328-333.

Research output: Contribution to journalArticle

McNulty, SN, Schwetye, K, Goldstein, M, Carter, JH, Schmidt, RE, Ansstas, G, Tsien, CI, Kim, AH & Dahiya, S 2018, 'Analysis of point mutations and copy number variation in Grade II and III meningioma', Experimental and Molecular Pathology, vol. 105, no. 3, pp. 328-333. https://doi.org/10.1016/j.yexmp.2018.10.007
McNulty, Samantha N. ; Schwetye, Katherine ; Goldstein, Michael ; Carter, Jamal H. ; Schmidt, Robert E. ; Ansstas, George ; Tsien, Christina I. ; Kim, Albert H. ; Dahiya, Sonika. / Analysis of point mutations and copy number variation in Grade II and III meningioma. In: Experimental and Molecular Pathology. 2018 ; Vol. 105, No. 3. pp. 328-333.
@article{55eb6a23030340a884983c4eaf5024af,
title = "Analysis of point mutations and copy number variation in Grade II and III meningioma",
abstract = "Meningiomas are among the most common tumors of the adult central nervous system (CNS). They are classified by the World Health Organization into three pathologic grades with increasing severity: grade I are benign with favorable treatment outcomes and low recurrence rates while grade III display malignant behavior and poor progression-free survival. Previous studies have shown that inactivation of NF-2 is the most common genetic event in high-grade meningioma; however, there is dearth of molecular data to distinguish grade II (AM-II) from the even more aggressive grade III (AM-III). As part of a routine diagnostic workup, 19 AM-II and 5 AM-III were submitted for targeted sequencing on a panel of twenty-four genes relevant to CNS tumors. The data generated during the course of clinical care was collected and re-analyzed with the aim of identifying molecular features to distinguish AM-II and AM-III. Our cases contained several well-characterized, potentially actionable mutations, but we did not find any novel, recurrent sequence variants. Copy number variations were common in both AM-II and AM-III; chr22q loss was the most prevalent followed in decreasing frequency by losses of chr1p, chr14q, and chr10. In particular, chr10 loss was noted in 4 of 5 AM-III cases but none of the AM-II cases. This suggests that chr10 loss may serve as a diagnostic and perhaps a prognostic marker to differentiate AM-II from AM-III. If confirmed in larger studies, our finding could further aid the classification of meningioma.",
keywords = "Clinical sequencing., Copy number variation., Meningioma, Next-generation sequencing.",
author = "McNulty, {Samantha N.} and Katherine Schwetye and Michael Goldstein and Carter, {Jamal H.} and Schmidt, {Robert E.} and George Ansstas and Tsien, {Christina I.} and Kim, {Albert H.} and Sonika Dahiya",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.yexmp.2018.10.007",
language = "English (US)",
volume = "105",
pages = "328--333",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Analysis of point mutations and copy number variation in Grade II and III meningioma

AU - McNulty, Samantha N.

AU - Schwetye, Katherine

AU - Goldstein, Michael

AU - Carter, Jamal H.

AU - Schmidt, Robert E.

AU - Ansstas, George

AU - Tsien, Christina I.

AU - Kim, Albert H.

AU - Dahiya, Sonika

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Meningiomas are among the most common tumors of the adult central nervous system (CNS). They are classified by the World Health Organization into three pathologic grades with increasing severity: grade I are benign with favorable treatment outcomes and low recurrence rates while grade III display malignant behavior and poor progression-free survival. Previous studies have shown that inactivation of NF-2 is the most common genetic event in high-grade meningioma; however, there is dearth of molecular data to distinguish grade II (AM-II) from the even more aggressive grade III (AM-III). As part of a routine diagnostic workup, 19 AM-II and 5 AM-III were submitted for targeted sequencing on a panel of twenty-four genes relevant to CNS tumors. The data generated during the course of clinical care was collected and re-analyzed with the aim of identifying molecular features to distinguish AM-II and AM-III. Our cases contained several well-characterized, potentially actionable mutations, but we did not find any novel, recurrent sequence variants. Copy number variations were common in both AM-II and AM-III; chr22q loss was the most prevalent followed in decreasing frequency by losses of chr1p, chr14q, and chr10. In particular, chr10 loss was noted in 4 of 5 AM-III cases but none of the AM-II cases. This suggests that chr10 loss may serve as a diagnostic and perhaps a prognostic marker to differentiate AM-II from AM-III. If confirmed in larger studies, our finding could further aid the classification of meningioma.

AB - Meningiomas are among the most common tumors of the adult central nervous system (CNS). They are classified by the World Health Organization into three pathologic grades with increasing severity: grade I are benign with favorable treatment outcomes and low recurrence rates while grade III display malignant behavior and poor progression-free survival. Previous studies have shown that inactivation of NF-2 is the most common genetic event in high-grade meningioma; however, there is dearth of molecular data to distinguish grade II (AM-II) from the even more aggressive grade III (AM-III). As part of a routine diagnostic workup, 19 AM-II and 5 AM-III were submitted for targeted sequencing on a panel of twenty-four genes relevant to CNS tumors. The data generated during the course of clinical care was collected and re-analyzed with the aim of identifying molecular features to distinguish AM-II and AM-III. Our cases contained several well-characterized, potentially actionable mutations, but we did not find any novel, recurrent sequence variants. Copy number variations were common in both AM-II and AM-III; chr22q loss was the most prevalent followed in decreasing frequency by losses of chr1p, chr14q, and chr10. In particular, chr10 loss was noted in 4 of 5 AM-III cases but none of the AM-II cases. This suggests that chr10 loss may serve as a diagnostic and perhaps a prognostic marker to differentiate AM-II from AM-III. If confirmed in larger studies, our finding could further aid the classification of meningioma.

KW - Clinical sequencing.

KW - Copy number variation.

KW - Meningioma

KW - Next-generation sequencing.

UR - http://www.scopus.com/inward/record.url?scp=85054787170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054787170&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2018.10.007

DO - 10.1016/j.yexmp.2018.10.007

M3 - Article

C2 - 30316860

AN - SCOPUS:85054787170

VL - 105

SP - 328

EP - 333

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 3

ER -